
Human Protein SSX2 103-111, RLQGISPKI
Description
About Human Protein SSX2 103-111, RLQGISPKI
The Human Protein SSX2 Peptide (IEDB: 138807) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Protein SSX2 Peptide, H-RLQGISPKI-OH (Uniprot: Q16385 aa: 103-111) from JPT is produced under strict quality control and quality management.
Human Protein SSX2 103-111, RLQGISPKI - Specifications
- Peptide sequence: H-RLQGISPKI-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Prostate cancer, Hepatocellular carcinoma
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Protein SSX2 103-111, RLQGISPKI
References:
Read References with JPT’s Antigen Peptides
Human Protein SSX2 103-111, RLQGISPKI has been described in:
Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor., Immunol Lett, 2009 (PMID: 19524620)
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells., J Immunother, 2011 (PMID: 21904219)
Documentation
Documentation for Human Protein SSX2 103-111, RLQGISPKI
Properties
Properties of Human Protein SSX2 103-111, RLQGISPKI
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Hepatocellular carcinoma, Prostate cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Protein SSX2 103-111, RLQGISPKI
Information | Values |
---|---|
Sequence: | H-RLQGISPKI-OH |
Specifications: | 9mer peptide as TFA salt |